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Head and neck squamous cell carcinoma (HNSCC)
is the sixth most common cancer worldwide (1) and it
accounts for 30-40% of all cancer types in Indian sub-
continent (2). The epidemiological studies have identi-
fied different etiological factors (e.g. tobacco, betel nut
leaf quid, alcohol), some environmental factors and
infection with oncogenic genotypes of human papillo-
mavirus (HPV), responsible for the development of
HNSCC (3,4). Among the HPVs, the high risk HPV-16
and 18 are most prevalent in the HNSCC tumors (5).
But, the role of these etiological factors in the initiation
and progression of this tumor is not clear.
The allelotyping studies (using microsatellite mark-
ers) of HNSCC have identified >30% loss of heterozy-
gosities (LOHs) in several chromosomal regions e.g.
3p, 5q, 6p, 8p, 9p, 9q, 11p etc. (6). Among these delet-
ed chromosomal regions, the loss in chr.9p21 region
has been proposed to be necessary for the development
of benign or precursor squamous hyperplasia of head
and neck lesions (7,8). Various other laboratories have
also reported similar high frequency of LOHs in the
chr.9p21-22 region of this tumor along with
microsatellite size alterations (MAs) in chr.9 (3,9). A
candidate TSG, p16 (cdk4/6 inhibitor), has been iden-
tified in the chr.9p21 region and the inactivation of this
gene either by mutation, deletion or hypermethylation
has been seen in HNSCC tumors (10). But Nagai (8)
suggested that the inactivation of P16 might be neces-
sary for the development of carcinoma-in-situ from
dysplastic lesions. This indicates that there might be
another tumor suppressor gene (TSG) present in this
region, required for the development of hyperplastic
lesions from normal mucosa. On the other hand, the
importance of chr.9q deletion in the progression of
HNSCC has not yet been studied in detail though El-
Naggar et al (11) have suggested that the LOHs at cer-
tain loci of chr.9q might be associated with the devel-
opment of HNSCC. However, no one has detected any
deletion in other regions of chr.9 in HNSCC, though
some of the regions e.g. 9p23-24 (12), 9q11-12 (13),
9q22.3 (14) and 9q32 (15), have been shown to be nec-
essary for the development of other tumors. This might
be due to the focussed analysis in certain regions of
chr.9 in HNSCC tumors. 
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In the deletion mapping of chromosome (chr) 9 in head and neck lesions of the Indian patient population by mi-
crosatellite markers, we have identified four discrete areas (D1-D4) with high loss of heterozygosities (LOHs)
viz. 9p24-p23 (D1), 9p22-p21 (D2), 9q11-q13 (D3) and 9q22.3 (D4) regions. The deletions in D2 and D4 regions
were suggested to be essential for the development of dysplastic lesions of head and neck, whereas the deletions
in D1 and D3 regions were responsible for progression of the dysplastic lesions to early invasive head and neck
squamous cell carcinoma (HNSCC). The microsatellite size alterations (MAs) were observed in the chromoso-
mal 9pter-p23, 9p22-p21(D2), 9q13 and 9q21.1-q21.2 regions with gradual increase during progression of the tu-
mor. Additional chromosomal alterations like loss of normal copy of chr.9 and biallelic alterations were also seen
in our samples. There is a correlation between HPV infection with TNM stages, histopathological grades and
LOHs at D1 and D4 regions. Whereas tobacco habit is associated with the occurrence of LOHs at D1 and LOHs
/ MAs at D2 region. 
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Thus, in the present study attempts have been made
to delineate the deletions in different regions of chr.9
(seen in HNSCC and other tumors) necessary for the
development of HNSCC. We have done this deletion
mapping at 22 microsatellite marker loci from both
arms of chr.9 in 24 primary dysplastic lesions, 34
stage-I/II and 40 stage-III/IV tumors from head and
neck regions of Indian patient population. Also, the
probable association of these changes with different
clinicopathological parameter including tobacco
intake, HPV-16/18 has been investigated. 
Materials and Methods
Sample collection and clinical data. Ninety-eight
freshly operated specimens from head and neck region
of 97 patients were collected along with their corre-
sponding normal tissue or peripheral blood leukocytes
(PBL) from Chittaranjan National Cancer Institute,
and Cancer Center & Welfare Home, Calcutta. The
detailed clinical history of the patients is presented in
Table I. The primary tumor (A) of one patient (# 5090)
at inner side of the cheek was collected along with his
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Table I - Clinicopathological features and HPV status of head and neck lesions 
Clinical Patient No. Median Age Age Range HPV -16/-18     Positivity
Features Years Years HPV+ HPV- Percentage P value
PRIMARY SITE
Oral cavity 79 49 8-76 46 33 58.0
Larynx 8 61 48-75 07 01 87.5 0.174
Orofacial 11 44 22-70 08 03 72.7
TNM STAGE
Dysplasia 24 48 32-70 09 15 37.5
Stage I 6 54 45-65 03 03 50.0
Stage II 28 49 8-76 16 12 57.0 0.0001
Stage III 28 51 30-70 21 07 75.0
Stage IV 12 51 26-70 12 00 100.0
GENDER
Male 79 48 8-76 51 28 64.5 0.251
Female 18 46 26-62 09 09 50.0
TUMOR 
DIFFERENTIATION*
Well 41 52 22-76 25 16 61.0
Moderate 26 48 8-70 20 06 77.0 0.024
Poor 7 50 32-75 07 00 100.0
LYMPH NODE
Positive 36 48 26-70 25 11 69.4 0.879
Negative 38* 50 8-76 27 11 71.0
TOBACCO
Tobacco + 53 44 22-76 35 18 66.0 0.4005
Tobacco - 45 49 8-75 26 19 58.0
*Excluding dysplasia
tumor of secondary recurrence (B) on the tooth gum.
The secondary tumor formation took place after 6
months of operation of the primary tumor. Out of 98
collected specimens, 2 (# 5090B and 333) were tumors
of secondary recurrence.  All the samples were collect-
ed after obtaining consent from the patients as well as
hospital authorities. Among the orofacial samples, 4
were from maxilla, 3 were from mandible and nasal
cavity each and 1 was collected from the cheek. The
samples were frozen immediately after collection and
stored at -80°C until use. The tumors were graded and
staged according to the UICC TNM classification.  The
patients were considered as tobacco habituated if they
consumed at least 10-15 cigarettes/bidis or equivalent
amount of chewable tobacco per day for at least 10
years.
Microdissection and DNA extraction. The
microdissection procedure was used to remove the nor-
mal cells present as contaminant in the specimens (16).
After microdissection, samples containing >60% dys-
plastic epithelium / tumor cells were taken for DNA
extraction. DNA was extracted by proteinase-K diges-
tion followed by phenol: chloroform extraction (16).
When the adjoining normal tissue of the lesion was
contaminated with infiltrating tumor cells, then PBL
was taken for normal DNA extraction. 
Microsatellite analysis. The location of the
microsatellite markers of chr. 9 and the genetic dis-
tances among them are mentioned in Table II. The
markers were selected from the different deleted
regions seen in HNSCC and other tumors (7,12-15).
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Table II - Overall patterns of LOHs and MAs of the microsatellite markers in dysplastic head and neck lesions and
invasive HNSCC samples
* D9S54 is located approximately 6.9 cM from the chr.9p telomere. D1-4: Highly deleted chr.9 regions.
Microsatellite 
Markers
D9S54
D9S1810
D9S1849
D9S168
D9S269
D9S157
D9S942
D9S171
D9S169
D9S104
D9S163
D9S15
D9S153
D9S257
D9S12
D9S197
D9S280
D9S1851
D9S287
D9S180
KM9.2
D9S103
Cytogenetic
Position
9pter-24
9p24-23
9p24-23
9p23
9p23
9p22-21
9p21
9p21
9p21
9p21-13
9q11-13
9q13
9q13
9q21.1-21.3
9q22.2-22.3
9q22.2-22.3
9q22.2-22.3
9q22.2-22.3
9q22.2-22.3
9q22.2-22.3
9q32
9q34
Genetic
Distance
cM
*
5.88
2.55
6.55
2.19
8.17
5.49
5
6.47
2.61
12
4.12
11.1
12.8
8
1.02
0.38
1.43
0
1.6
20.5
6.57
LOH
% (No)
0 (0/5)
0 (0/16)
7 (1/14)
10 (2/19)
0 (0/6)
33 (3/9)
21 (4/19)
0 (0/13)
0 (0/10)
18 (3/16)
0 (0/15)
5 (1/17)
10 (1/10)
5 (1/19)
0 (0/16)
32 (6/19)
31 (5/16)
26 (5/19)
0 (0/6)
0 (0/6)
0 (0/10)
0 (0/7)
MA
% (No)
27 (3/11)
4.5 (1/11)
5 (1/18)
4.7 (1/21)
8 (1/12)
48 (10/21)
19 (4/21)
0 (0/21)
0 (0/11)
12 (3/24)
0 (0/23)
4.3 (1/23)
0 (0/10)
9 (2/22)
10 (2/20)
0 (0/17)
0 (0/17)
5.8 (1/17)
0 (0/22)
0 (0/11)
0 (0/11)
0 (0/12)
LOH
% (No)
15 (6/39)
42.8 (21/49)
47 (24/51)
36 (17/47)
16 (6/37)
31 (15/48)
23 (13/56)
21 (9/34)
19 (9/47)
21 (7/33)
36.8 (14/38)
14.8 (7/47)
21 (10/41)
22.6 (7/31)
25.7 (9/35)
36 (14/39)
29 (12/42)
30 (14/47)
27 (10/37)
21.6 (8/37)
19 (9/47)
21 (8/37)
MA
% (No)
24 (13/54)
25 (12/48)
25 (14/55)
23.6(13/55)
10 (6/59)
20.8(10/48)
25 (15/60)
12 (8/66)
18 (11/60)
16 (8/48)
15.8(10/66)
23.3(14/60)
16.6(10/60)
25.9(14/54)
18.3(9/49)
20 (12/59)
9.5(4/42)
14 (7/49)
14.8(8/54)
14.8(8/54)
19 (11/56)
6.2 (4/64)
D1
D2
D3
D4
Dysplastic Lesions Invasive HNSCC
Primer sequences of these markers were obtained from
Genome Database except the marker KM9.2 (15). The
PCR was performed in a 20 µl reaction volume con-
taining 67 mM Tris (pH 8.7), 16.6 mM (NH4)2SO4, 1-
2 mM MgCl2, 0.01% Tween-20, 4 pmol of each
primer, 0.2 mM of each dNTPs, 50-100ng of template
DNA and 0.5 units of Taq-DNA polymerase (Gibco-
BRL, USA) as described by Dasgupta et al, (16). One
of the paired primers in the reaction mixture was end
labeled with [γ32p] ATP (specific activity
3000ci/mmol, Amersham, U.K.) using T4-Polynu-
clotide kinase (Gibco-BRL, USA). The PCR condi-
tions were 95°C for 5 min, then 30 cycles at 95°C for
1 min, annealing at appropriate temperature (50-62°C)
for 1 min and extension at 72°C for 2 min followed by
final extension at 72°C for 7 min. The labeled PCR
products were electrophoresed in 7% polyacrylamide
gel containing 8M urea and autoradiographed as
described by Dasgupta et al (16). 
In our analysis, the microsatellite markers could
detect LOHs and MAs in the presence of 50% and 10-
30% tumor DNA, respectively (16). The LOHs were
interpreted for all informative (heterozygous) cases by
densitometric scanning (Shimadzu, CS-900) of the
autoradiographs. The allelic loss was recorded if there
was a complete absence of one allele or if the relative
band intensity of one allele was reduced at least 50% in
the tumor in comparison to the homologous allele in the
corresponding normal DNA (16,17). The MAs were
detected by a shift in the mobility of one (MA1) or both
(MA2) alleles in comparison to the same alleles in the
corresponding normal DNA (18). The samples showing
loss of one allele and size alteration of the other allele
(LOH+MA) at the same locus was considered for cal-
culating both LOH and MA. The calculations of LOHs
and MAs as well as proper pairing of the samples were
done according to Dasgupta et al (16). 
Detection of HPV-16 and 18. The presence of HPV
in the head and neck lesions was detected by perform-
ing PCR using primers (MY09 and MY11) from the
consensus L1 region (19). The typing of HPV-16/ 18 in
the L1 positive samples was done by PCR using spe-
cific primers from the HPV-16 E6 (20) and HPV-18
E7 (21) region. The PCR products were elec-
trophoresed in 2% agarose gel and stained with ethidi-
um bromide for visualisation under UV-light and pho-
tographing. For final confirmation of the HPV types,
the PCR products after gel electrophoresis were trans-
ferred to the nylon membrane for southern hybridiza-
tion with 32p-labelled HPV type specific probes (5).
As a positive control for HPVs, the DNAs from SiHa
(for HPV-16) and HeLa (for HPV-18) cell lines and
the HPV type specific plasmids were used.
Statistical analysis of the clinical data. To deter-
mine the association between high LOH/MA regions
and different clinicopathological features (tobacco
habit, nodes at pathology, tumor stages and HPV infec-
tion) of the tumors the Chi-square analysis was per-
formed. Probability values of P<0.05 was regarded as
statistically significant.
Results
Analysis of allelic alterations (LOHs/MAs) in the
samples. In this analysis we have seen different types
of allelic alterations i.e., LOHs, MA1, MA2 and
LOH+MA (loss of one allele and size alteration of the
other allele) in the samples (Figs 1 & 2).  The allelic
alterations (LOHs and / or MAs) have been seen at
chr.9p and 9q in 70% (69/98) and 59% (58/98) of the
samples respectively, indicating the importance of both
arms of chr.9 in the development of HNSCC.
In the 74 HNSCC samples analysed, the highest
frequencies of LOHs of 36-47%, 23-31%, 37% and 29-
36% were seen in the 9p24-23 (D9S1810, D9S1849
and D9S168): D1, 9p22-21 (D9S157, D9S942): D2,
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Fig. 1 - Representative photograph showing LOHs and MAs at
different marker loci on chr. 9 in different head and neck
samples. T: DNA of the dysplastic/ tumor cells after mi-
crodissection; N: corresponding normal tissue or PBL.
? Indicates loss of the corresponding allele; 
? indicates size alteration of one or both alleles.
9q11-13 (D9S163): D3 and 9q22.3 (D9S197, D9S280
and D9S1851): D4 regions, respectively (Fig.2 &
Table II).  On the other hand, in the dysplastic lesions
highest frequency of LOHs of 21-33% and 26-32%
were seen only in the D2 and D4 regions, respectively.
Whereas, only 7-10% of LOHs were detected in the D1
region and without any LOHs in the D3 region in dys-
plastic samples. 
In the HNSCC samples, the highest frequency of
MAs (20-26%) were seen in the 9p23-24, 9p21-22,
9q13, 9q21.1-21.3 and 9q22.3 regions (Table II). Inter-
estingly most of the high MA regions were coincident
in and around the high deleted regions except D3.
Seven tumors at stage-III/IV and 1 tumor at stage-II
showed allelic alterations (LOHs and/or MAs) in all
the markers studied indicating probable absence of
normal copy of chr.9 in these tumors (Fig.2). In the
analysis of primary (A) and recurrent (B) tumors of
patient #5090, it was seen that both the samples
showed same pattern of allelic alterations along with
additional LOHs at four loci in the recurrent tumor
(Fig.2). However, unlike HNSCC tumors, very low
MAs were seen in D1, D3 and D4 regions in the dys-
plastic lesions except in the D2 region where 19-48%
MAs were observed.
Consistent homozygous loss at any marker loci is
supposed to be the location of putative TSG(s). In this
study, we did not find any homozygous deletion i.e.
loss of both alleles, but in 41 samples some markers
showed either MAs of both alleles (MA-2) or MA of
one allele and loss of the other allele (LOH+MA)
(Figs.1&2). In chr.9p, the biallelic alterations were
found to be concentrated in the D1 and D2 regions
whereas in chr.9q the high biallelic alteration was seen
in the 9q21.1-21.3 (D9S257) region. 
HPV-16/18 infection in the head and neck lesions.
The prevalence of HPV was detected in 62% (61/98)
of the samples (Table I and Fig.2). However, majority
of the HPV positive samples (60/61) was found to be
infected with HPV16 and only one sample (#1367)
seemed to be infected with HPV18 (Fig.2). The HPV
infection was significantly associated with tumor
stages and grades (Table I).
Deletions in both Arms of Chromosome 9 are Responsible for HNSCC Development
293
Fig. 2 - Allele status of the chr.9 markers in the HNSCC samples that showed alteration.
LOH , MA-1 , MA-2 , LOH+MA , RH ,  NI , ND 
LOH: Loss of heterozygosity, MA-1: Microsatellite size alteration of one allele, MA-2: Microsatellite size alterations of both al-
leles, LOH+MA: Loss of one allele and size alteration of the other allele, RH: Retention of heterozygosity, NI: Noninformative,
ND: Not done, A: HPV absent, 16: HPV-16 present, 18: HPV-18 present. D1-4: Highly deleted regions.
Clinicopathological correlation of the allelic alter-
ations. It was evident from Fig. 3 that the high inci-
dences of LOHs at D2 and D4 regions were present in
the dysplastic lesions and remain more or less constant
(in case of D2)or increased (in case of D4) in the later
stages of the tumor. Thus, it indicated that the deletions
in these regions were necessary for the development of
dysplastic head and neck lesions. But the LOHs in the
D1 and D3 regions were seen to be significantly asso-
ciated with the progression of the dysplastic lesions to
the stage-I/II HNSCC tumors (P value: 0.018-0.02)
(Fig. 3). The D1 region was associated with the nodal
involvement of the tumor, HPV positivity and tobacco
habits (P value: 0.012-0.047)(Table III). Whereas, the
D2 and D4 regions were associated with tobacco habits
and HPV positivity of the samples, respectively.  On
the other hand the MAs in the D1 and D2 regions were
seen to be associated with the progression of the tumor
(P value: 0.026) and the tobacco habits (P value:
0.029), respectively.
Discussion
Among the four highly deleted regions, the D2
region (Fig.2 and Table II) overlapped with the regions
reported by other investigators in HNSCC tumors, lung
carcinoma, melanoma, etc. (7,22). Whereas the dele-
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Table III - Clinicopathological correlation of the regions that showed high LOHs and MAs
(a): Correlation of the four high LOH regions
Table III (b): Correlation of the four high MA regions
tions in D1, D3, D4 regions (Fig. 2 and Table II) were
coincident with the deleted regions seen in the carci-
nomas of breast, bladder, and basal cell etc. (12-14).
The identical frequencies of deletions in the D2 and D4
regions in both dysplastic lesions and HNSCC tumors
have indicated that deletions in these regions were
associated with the development of dysplastic lesions
(Fig.3). Others have also reported the involvement of
D2 region in the early stages of head and neck cancer
(7,9). We have narrowed down this deleted region
within 5.5 cM (D9S157-D9S942) (Fig.2). Between the
D9S157 and D9S942 markers, comparatively high
LOHs were observed in the D9S157 locus though
D9S942 marker was 5 kb upstream of the putative
tumor suppressor gene, P16. Thus, it seems that the
candidate TSG(s) responsible for the pre-malignant
lesion may be located near the D9S157 locus. Similar-
ly, using microcell hybrid system Parris et al (23) sug-
gested the location of a new TSG in 9p21 region,
telomeric to P16 gene. However, to rule out the possi-
bility of P16 involvement in the development of pre-
malignant head and neck lesions, the other mecha-
nisms of P16 inactivation i.e. mutation, methylation
etc., should be studied in same set of samples along
with the deletion mapping. We have localized the D4
region within 1.81 cM of 9q22.2-22.3 (D9S197-
D9S1851). Among the three markers in the D4 region,
the D9S280 and D9S1851 markers were in close vicin-
ity of two important genes e.g. FACC (Fanconi's
anaemia complementation group C) and PTC (candi-
date TSG for bladder cancer and nevoid basal cell car-
cinoma). But the importance of these genes in the
development of HNSCC has not yet been studied. 
The significant increase of LOHs in the D1 and D3
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Fig. 3 - Pattern of deletion in the D1-D4 regions of Chr. 9 during HNSCC development. The lesions showing MA and NI at all the mark-
ers of a particular deleted region were not considered for LOH calculation of that region.
regions in stage-I/II tumors than the dysplastic lesions
has suggested that the deletions at these sites are asso-
ciated with the progression of dysplastic lesions to
early invasive tumors (Table III, Fig.3). We have nar-
rowed down the D1 region within 9.1 cM of 9p23-24
region. Though a novel oncogene GASC1 (Gene
amplified in squamous cell carcinoma) responsible for
esophageal cancer (24) and an important signal trans-
duction gene, JAK2 (Janus kinase2), were present in
this region, yet no candidate TSG has been identified
from this region.  On the other hand, we have used only
one marker (D9S163) from the D3 region. For exact
localization of TSG loci more markers should be stud-
ied from this region. 
Similar to our results, differential losses at different
regions of chr.3 was reported to be essential for the
development of lung carcinoma (18) and HNSCC (our
unpublished data). Also, Huebner K proposed that for
the development of lung, kidney and other cancers
compound mutations at different TSGs located in dif-
ferent regions of chr.3p were necessary (25).
Recently, two candidate TSGs e.g. GAS1 (Growth
arrest specific gene1) at chr.9q21.3-22 (26) and DEC1
(Deleted in esophageal cancer1) at chr.9q32 (27) were
shown to be responsible for the development of blad-
der carcinoma and esophageal carcinoma, respectively.
Also, El-Naggar et al (11) showed total 35% LOHs in
chr.9q using three markers from the 9q13-21, 9q31-33
and 9q34-ter regions in HNSCC samples. But we have
not seen high LOHs in these regions.
In contrast to the HNSCC tumors, dysplastic
lesions showed high MAs only in the D2 region par-
ticularly in the D9S157 marker (Fig.2 & Table II).
Thus, the MAs may not be the early event in this
tumorigenesis. Other investigators in their analysis of
molecular abnormalities (LOHs and MAs) also report-
ed similar phenomenon on chr.3 in the HNSCC
(16,28). The presence of comparatively high biallelic
alterations in and around the high molecular abnormal-
ity regions (except D4) indicates that the LOHs or
MAs in one allele of these regions may impose selec-
tive pressure on the other allele of the same locus for
deletion or size alteration (Fig.2). Also probable loss of
normal copy of chr.9 mainly in late stages of the tumor
may provide some growth advantage in this tumor pro-
gression. Similar phenomena have been reported in the
analysis of other chromosomes in HNSCC tumors
(16,29). Thus, during progression of the tumor a) the
gradual increase of MAs, b) loss of normal copy of
chr.9, c) interstitial alterations (LOHs and MAs) and d)
the occurrence of LOHs at additional loci in the recur-
rent tumor (#5090), indicate that additional genetic
alterations are necessary for clonal outgrowth of a sub-
population of cells for subsequent tumor progression
(Fig.2). The etiological factors like tobacco intake and
HPV positivity might have some role in this tumorige-
nesis due to the significant association of these factors
with some deleted regions. Also, the association of
deletion at D1 region with the nodal involvement of
the tumor has indicated its necessity in this tumor pro-
gression. 
Thus, it can be concluded from our analysis that dif-
ferential deletions in four highly deleted regions (D1-
D4) of chr.9 in head and neck lesions are needed for
the development of specific stages of HNSCC progres-
sion. The loss of function of TSGs located at these
regions may have sequential cumulative effect in this
tumor progression. Along with these deletions, other
molecular changes in the chromosome, like MAs,
interstitial alterations and loss of normal copy of chr.9
may have some role in this tumor progression by
imposing some selective pressure for growth advan-
tage of the tumor.
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